New KETO-CTA Data - Clarification and Update on Cleerly скачать в хорошем качестве

New KETO-CTA Data - Clarification and Update on Cleerly

In this talk, Dave Feldman shares new updates from the Keto-CTA study, comparing results across four independent CT imaging analyses: Cleerly, QAngio, HeartFlow, and semi-quantitative reads by expert readers. He addresses the controversies around LDL-C, ApoB, plaque progression, and regression, revealing why certain datasets conflict, and presents compelling evidence showing verified plaque regression in a subset of participants. (* This talk was provided courtesy of Symposium for Metabolic Health 2025. https://www.lowcarbusa.org/ ) 0:00 – Intro & welcome 0:34 – Disclosures & background on the Keto-CTA study 1:01 – Study design & lean mass hyper-responder criteria 1:45 – CT scans, imaging methods & data acquisition 2:10 – Semi-quantitative vs quantitative analysis explained 3:06 – Timeline of analyses & initial expectations 3:29 – First Cleerly results & early concerns 4:11 – Shared findings: baseline plaque & lack of LDL/ApoB association 5:21 – Paper publication & critics’ reactions 6:07 – Prespecified methodology: why QAngio matters 6:59 – Social media debates & misinterpretations 7:33 – The “limited contrast” argument emerges 8:33 – Breaking down claims about “all high LDL” 9:42 – Visualizing the actual LDL spread 11:01 – LDL variability: 49 mg/dL to 591 mg/dL 12:30 – Problems with the “limited exposure” critique 13:08 – Revisiting the lipid hypothesis: dose-dependent effects 14:07 – Are these the “healthiest” participants? Context & caveats 15:14 – Participant risk factors: CAC scores, A1C, glucose, hs-CRP 16:33 – Why Dave reduced public debates for a time 17:01 – Issues discovered in Cleerly’s dataset 18:13 – Introducing HeartFlow: a blinded independent analysis 19:05 – Why a fourth analysis was critical 20:02 – Record-breaking multi-analysis study design 20:34 – Preliminary results warning 21:04 – Non-calcified plaque volume % change: conflicting findings 22:00 – Absolute vs relative change: why it matters 22:28 – Total plaque volume & percent atheroma volume 23:17 – How HeartFlow & QAngio compare to reference studies 24:40 – Top-level observations & agreements 25:07 – Plaque regression: the star of the show 26:14 – Direct verification of regression by Dr. Budoff 27:00 – Red flags in Cleerly’s data: no negative values 28:33 – The “noise floor” problem explained 30:28 – Why multiple analyses were necessary 31:15 – Every imaging study shows regression — except Cleerly 32:02 – Statistical implausibility of Cleerly’s results 32:37 – Final conclusions on regression evidence 33:29 – Does regression imply safety for lean mass hyper-responders? 34:11 – No association of LDL/ApoB with plaque presentation or progression 35:02 – What’s next: study extension & Triad study 35:38 – Reflecting on six years since Keto-CTA’s conception 36:32 – Acknowledgments & closing remarks #cardiovascularhealth #ketodiet #cholesterol #apoB #hearthealth #heartdisease #atherosclerosis #educational #sciencecommunication #ketosis #keogenic #HDL #LDL #triglycerides #metabolichealth #metabolism #atherosclerosis #plaqueregression